RHB-107
Cancer (Solid Tumors)
Phase 1/2Active
Key Facts
About RedHill Biopharma
RedHill Biopharma is a publicly traded, Israel-based company dedicated to developing and commercializing novel, primarily oral, small-molecule drugs for significant unmet medical needs. Its strategy integrates in-house R&D with strategic acquisitions to build a portfolio focused on GI diseases, infectious diseases, and oncology. A key achievement is establishing a late-stage pipeline of host-directed oral antivirals designed as broad-spectrum, mutation-resistant medical countermeasures suitable for government stockpiling.
View full company profileTherapeutic Areas
Other Cancer (Solid Tumors) Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Antibody Programs | New Paradigm Biosciences | Pre-clinical |
| Not Publicly Disclosed | HighPassBio | Pre-clinical |
| STEM-T enhanced TCR-T | Immunova Therapeutics | Pre-clinical |